Last reviewed · How we verify

NCT03716934: craft

CRyoAblation vs AntiaRrhythmic Drugs for Persistent Atrial Fibrillation Trial

Completed Phase 4 Last updated 15 September 2025
What this trial tests

Phase 4 trial testing Arctic Front Advance® balloon catheter in Atrial Fibrillation in 196 participants. Completed in 18 April 2022.

Timeline
27 June 2018
Primary endpoint
18 April 2022
18 April 2022

Quick facts

Lead sponsorHospital San Carlos, Madrid
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment196
Start date27 June 2018
Primary completion18 April 2022
Estimated completion18 April 2022
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Hospital San Carlos, Madrid

Who can join

Adults 18 to 75, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, randomized, multicenter study comparing the relative efficacy and safety of cryoablation of PVs using the Arctic Front Advance® balloon catheter with antiarrhythmic therapy in patients with persistent AF.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Hospital San Carlos, Madrid trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03716934.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing